Capricor Therapeutics Inc. (NASDAQ: CAPR ) faces heightened shareholder pressure as investment firm Kaos Capital Ltd. on Friday issued a formal letter requesting an immediate meeting with the board of directors to demand a comprehensive governance reset, aggressive cash preservation measures, and a strategic realignment.
Kaos Capital intends to nominate two independent director candidates and establish an M&A and Strategic Alternatives Committee chaired by a shareholder-backed director to steer the company away from relying solely on its lead asset, deramiocel .
Capricor Therapeutics’ Soaring Expenses Spark Cash Preservation Push
Kaos Capital highlighted significant spending concerns, noting that Capricor reported $237.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026—marking an $80.2 million reduction from year-end 2025.
Total operating expenses reached $79.7 million during the first half of 2026, driven by $23.5 million in general and administrative expenses, which roughly doubled compared to the same period in 2025.
Consequently, the shareholder group urges the adoption of a formal Cash Preservation Plan, including a near-term freeze on nonessential spending and a zero-based review of administrative costs.
Read Next Trading IdeasCapricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy
Capricor stock plunged after an FDA panel questioned Deramiocel's effectiveness in DMD despite published Phase 3 HOPE-3 trial results.
3 min read Read this articleExpanding Beyond Single-Asset Risk
While recognizing the potential of deramiocel, Kaos Capital argued against concentrating all capital and future regulatory risk into a single outcome.
Trending Get a 1% Match on Your First Deposit of $1,000+The firm advocates using Capricor as a disciplined biotechnology platform, evaluating strategic acquisitions and partnerships in complementary areas such as inflammation, fibrosis, tissue repair, targeted delivery, and regenerative medicine to diversify risk and build long-term value .
Addressing Legal Overhang And Governance Oversight
To reduce ongoing costs and reputational risk, Kaos Capital requested that the board engage premier independent legal advisers to rapidly resolve multiple pending legal disputes and securities actions.
Furthermore, the investor called for an independent review of internal oversight processes to establish a constructive, shareholder-friendly corporate environment.
Capricor Therapeutics Price Action
CAPR Price Action: Capricor Therapeutics shares were down 8.92% at $6.22 at the time of publication on Friday, according to Benzinga Pro data .
Photo via Shutterstock
Read Next MoversRoss Stores CEO Says Retailer Is Snatching Market Share From Rivals
Ross Stores (ROST) surges in premarket after Q2 revenue beats at $6.27B and EPS hits $2.66. FY26 earnings guidance raised.
3 min read Read this article Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Movers News General Biotech Top Stories Health Care Why It's Moving Stories That Matter